at Zacks.com (Wed, 12:00PM)
Recent Phase III study results published in the New England Journal of Medicine show Novartis' (NVS) drug canakinumab significantly relieves symptoms in patients with a serious form of childhood arthritis. The drug was assessed in two trials and both showed canakinumab provided substantial symptom relief and delayed disease flare recurrence, thus allowing patients to substantially reduce or discontinue use of corticosteroids.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 3:46AM)
at Investor's Business Daily (Mon, 8:02AM)
at Zacks.com (Fri, 5:50PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs